DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: gadodiamide

Summary for Generic Name: gadodiamide

Tradenames:1
Patents:1
Applicants:1
NDAs:2
Drug Master File Entries: 0
Suppliers: see list1
Formulation / Manufacturing:see details

Pharmacology for Ingredient: gadodiamide

Clinical Trials for: gadodiamide

Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
Status: Completed Condition: Chronic Kidney Disease; Renal Insufficiency

A Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging
Status: Completed Condition: Coronary Artery Disease

A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide
Status: Completed Condition: Renal Artery Stenosis

A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-Iliac Arteries While Using Gadodiamide
Status: Completed Condition: Aorto-Iliac Stenosis; Arterial Occlusive Diseases

A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain
Status: Completed Condition: Brain Pathology

Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities
Status: Terminated Condition: Glioblastoma Multiforme

Comparative Study of Non-enhanced Versus Contrast Enhanced MR Angiography in Peripheral Arterial Disease on a 3T MR Scanner.
Status: Completed Condition: Peripheral Arterial Disease

Neurovascular Non Contrast-Enhanced MR Angiography at 3T
Status: Recruiting Condition: Neurovascular Diseases

Efficacy and Safety of Primovist in Chinese Patients
Status: Completed Condition: Known or Suspected Focal Liver Lesions

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ge Healthcare
OMNISCAN
gadodiamide
INJECTABLE;INJECTION020123Jan 8, 1993RXYes5,560,903<disabled>Y
Ge Healthcare
OMNISCAN
gadodiamide
INJECTABLE;INJECTION022066Sep 5, 2007RXYes5,560,903<disabled>Y
Ge Healthcare
OMNISCAN
gadodiamide
INJECTABLE;INJECTION022066Sep 5, 2007DISCNNo5,560,903<disabled>Y
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc